A Prospective NIS to Evaluate the Clinical Outcomes of Risarg ® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the Russia

Conditions: HR+HER2- Advanced Breast Cancer Interventions: Other: Ribociclib; Other: Combination chemotherapy Sponsors: Novartis Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials